drugset / Trial / NCT02567682

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

NCT02567682

Phase 1 Completed 24 enrolled Global Blood Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study to evaluate the effect of concomitant administration of GBT440 on caffeine (a CYP1A2 probe substrate), S warfarin (a CYP2C9 probe substrate), omeprazole (a CYP2C19 probe substrate), and midazolam (a CYP3A4 probe substrate) plasma concentrations.

Timeline

Start
2015-09
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule
Subject Midazolam Small molecule
Subject Omeprazole Other / unclassified
Subject S-warfarin Unknown
Subject Voxelotor Small molecule
Background Vitamin K Unknown

Indications